Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
ILMN [NASD]
Illumina Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E96.00 EPS (ttm)0.75 Insider Own1.48% Shs Outstand124.38M Perf Week2.89%
Market Cap8.96B Forward P/E36.36 EPS next Y1.98 Insider Trans-11.17% Shs Float122.78M Perf Month27.82%
Income102.47M PEG5.67 EPS next Q0.39 Inst Own- Short Float23.63% Perf Quarter47.75%
Sales1.21B P/S7.42 EPS this Y81.45% Inst Trans-0.22% Short Ratio21.84 Perf Half Y48.64%
Book/sh10.54 P/B6.83 EPS next Y17.86% ROA4.06% Target Price62.77 Perf Year61.54%
Cash/sh8.58 P/C8.39 EPS next 5Y16.92% ROE8.29% 52W Range37.77 - 77.11 Perf YTD29.52%
Dividend- P/FCF39.91 EPS past 5Y24.67% ROI4.72% 52W High-5.84% Beta0.66
Dividend %- Quick Ratio3.37 Sales past 5Y25.64% Gross Margin67.27% 52W Low92.24% ATR2.36
Employees2400 Current Ratio3.78 Sales Q/Q21.33% Oper. Margin8.78% RSI (14)78.11 Volatility3.18% 3.31%
OptionableYes Debt/Eq0.65 EPS Q/Q-193.23% Profit Margin8.49% Rel Volume0.56 Prev Close72.00
ShortableYes LT Debt/Eq0.62 EarningsApr 22 AMC Payout0.00% Avg Volume1.33M Price72.61
Recom2.40 SMA2010.31% SMA5022.97% SMA20041.14% Volume42,398 Change0.85%
23-Apr-13Reiterated UBS Buy $61 → $67
23-Apr-13Reiterated ISI Group Neutral $60 → $61.50
23-Apr-13Reiterated Cantor Fitzgerald Hold $48 → $53
09-Apr-13Reiterated Mizuho Buy $57 → $61
29-Jan-13Reiterated Cantor Fitzgerald Hold $45 → $48
04-Jan-13Downgrade Wedbush Outperform → Neutral
26-Nov-12Downgrade Robert W. Baird Outperform → Neutral $54
24-Apr-12Reiterated Mizuho Buy $62 → $52
19-Apr-12Reiterated Cantor Fitzgerald Hold $51 → $40
08-Feb-12Reiterated Barclays Capital Overweight $39 → $60
25-Jan-12Upgrade Robert W. Baird Neutral → Outperform $33 → $60
26-Oct-11Reiterated Barclays Capital Overweight $35 → $33
07-Oct-11Reiterated RBC Capital Mkts Sector Perform $72 → $29
07-Oct-11Downgrade UBS Buy → Neutral $80 → $32
07-Oct-11Downgrade Maxim Group Buy → Hold
07-Oct-11Downgrade Deutsche Bank Buy → Hold $52.50 → $30
27-Jul-11Reiterated Barclays Capital Overweight $78 → $74
27-Apr-11Reiterated Wedbush Outperform $75 → $80
27-Apr-11Reiterated RBC Capital Mkts Sector Perform $67 → $72
27-Apr-11Reiterated Deutsche Bank Buy $82.50 → $84
18-May-13 08:05AM  IBD 50: Top 5 Medical Stocks Include Celgene, Actavis at Investor's Business Daily
17-May-13 11:28AM  How one bull is sticking with Illumina optionMONSTER
16-May-13 03:39PM  A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical Companies Wall Street Transcript
02:00PM  Gene-Testing Dispute Focuses on How Much a Patient Should Know at Bloomberg
07:46AM  InPlay: Illumina guides FY13 below consensus at Proxy Roadshow Briefing.com
06:30AM  Illumina Launches BaseSpace® Apps Business Wire
15-May-13 02:30PM  Much Awaited Test Launch by Genomic Zacks
02:00PM  Myriad Soars Higher on Celeb Clout Zacks
09:19AM  Tyco Electronics CEO Sells More Than 59K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
06:36AM  Illumina to partner for automation of sample preparation kits theflyonthewall.com
06:30AM  Illumina Announces Partnerships to Automate TruSeq® and Nextera® Sample Preparation Kits Business Wire
05:53AM  The Hidden Opportunity of the Novel Coronavirus at Motley Fool
13-May-13 05:01PM  Illumina Inc. (ILMN): Today's Featured Drugs Laggard at TheStreet
03:47PM  Sequenom shares advance as analyst lifts rating AP
01:43PM  This Biotech Giant Is Continuing Its Growth via M&A at Motley Fool
10-May-13 04:40PM  Illumina Larger Than S&P 500 Component Ameren at Forbes
03:34PM  Illumina Rises On Unusually High Volume (ILMN) at TheStreet
08-May-13 12:54PM  Illumina Stock Hits New 52-Week High (ILMN) at TheStreet
07-May-13 01:04PM  ILLUMINA INC Financials EDGAR Online Financials
08:05AM  Spirit, Alaska Air Among Top 5 For Bolting RS Lines at Investor's Business Daily
01-May-13 11:08AM  Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs: A Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc. Wall Street Transcript
09:54AM  ILLUMINA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
06:30AM  Illumina to Webcast Live Presentation at Upcoming Investment Conferences in May Business Wire
30-Apr-13 02:07PM  Is Illumina's Stock Destined for Greatness? at Motley Fool
12:18PM  Illumina Reaches New 52-Week High (ILMN) at TheStreet
29-Apr-13 04:15PM  Qiagen buys genetic data processor Ingenuity for $105 million at Reuters
12:22PM  This Deal Brings Benefits Along With a Huge Debt at Motley Fool
27-Apr-13 04:01AM  [$$] Charting the Market at Barrons.com
26-Apr-13 06:35PM  Qihoo, Grifols Shape New Price Patterns at Investor's Business Daily
01:02PM  Hepatitis C Space an Opportunity with the Potential for an Upside Surprise, According to Expert Analyst David Ferreiro Wall Street Transcript
11:50AM  Wall Street Transcript Interview with William A. Hartman, President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI) Wall Street Transcript
25-Apr-13 04:10PM  InPlay: Illumina: Verinata Health publishes clinical laboratory performance data for verifi prenatal test; demonstrates verifi is highly accurate in detecting fetal chromosome abnormalities Briefing.com
04:05PM  Verinata Health Publishes Clinical Laboratory Performance Data for verifi® Prenatal Test Business Wire
11:20AM  Illumina's Solid Quarter Highlights Macroeconomic Resilience, Market Opportunity at Seeking Alpha
24-Apr-13 06:02PM  Nasdaq stocks posting largest percentage increases AP
01:28PM  Nasdaq stocks posting largest percentage increases AP
23-Apr-13 06:03PM  Nasdaq stocks posting largest percentage increases AP +13.28%
04:55PM  Illumina surges on 1Q stronger income and sales AP
03:00PM  Illumina Beats on Earnings, Revenue Zacks
12:36PM  Why Illumina Shares Soared at Motley Fool
11:46AM  Four Lessons From IBM And Roche's Failed DNA Collaboration at Forbes
11:39AM  Illumina Stock Soars On Q1 Earnings Beat at Investor's Business Daily
11:07AM  Analyst Moves: NFLX, ILMN, HAL at Forbes
11:01AM  Illumina Jumps Most in 15 Months on First-Quarter Profit at Bloomberg
10:58AM  Illumina leaps to a 13% gain despite reporting net loss during first quarter at MarketWatch
10:57AM  Illumina Flexes Its Muscles A Bit at Seeking Alpha
09:41AM  Earnings Roundup: DuPont, Illumina & Travelers at Barrons.com
05:41AM  U.S. Stock Futures Are Little Changed; Netflix Jumps at Bloomberg
22-Apr-13 11:00PM  Illumina Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
06:57PM  On The Fly: After Hours Movers at theflyonthewall.com
06:24PM  Illumina takes 1Q loss on Syntrix charge AP
05:19PM  Illumina Earnings: Heres Why Investors are Happy Now at Wall St. Cheat Sheet
05:00PM  Illumina, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN
04:49PM  Illumina, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN
04:40PM  After-Hours Buzz: NFLX, TXN, ZION & More at CNBC
04:26PM  BRIEF-Illumina shares up 4.3 pct after the bell at Reuters
04:09PM  InPlay: Illumina beats by $0.07, beats on revs Briefing.com
04:05PM  Illumina Reports Strong Start to Fiscal Year 2013 Business Wire
04:05PM  Illumina Names Charles Dadswell as Senior Vice President and General Counsel Business Wire
09:56AM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q1 2013 Illumina, Inc. Earnings Release - After Market Close CCBN
05:55AM  1 Biotech, 1 Financial And An Industrial Goods Company With Recent Intensive Insider Selling at Seeking Alpha
21-Apr-13 04:12AM  China Biotech In Review: Thermo Fisher Emerges Victorious In Battle To Acquire Life Technologies at Seeking Alpha
19-Apr-13 12:20PM  Thermo Steps Up And Seals A Deal For Life Technologies at Investopedia
18-Apr-13 01:47PM  Bulls Sweet On PepsiCo Calls As Shares Rise at Seeking Alpha
12:53PM  Money Pours Into PepsiCo Calls, Illumina Options Light Up Before Earnings at Forbes
12:16PM  5 Names Seeing Bullish Options Flow at TheStreet
06:30AM  Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate Clinical Adoption of Illumina Technologies in Asia Business Wire
17-Apr-13 10:54AM  Illumina: Thermo Fisher-Life Deal Unlikely To Threaten Its Market-Leading Position at Seeking Alpha
16-Apr-13 03:25PM  Around the Web: Gene mergers, more competition, fewer guarantees at MarketWatch
06:56AM  Thermo Fisher Buys Life Technologies At A Knock-Out Price at Seeking Alpha
15-Apr-13 05:07PM  Thermo Fisher Buying Life Tech At Premium Price at Investor's Business Daily
10:55AM  Sequencing Is Hot: Life Technologies Deal Has Implications For Illumina at Seeking Alpha
10:42AM  Is Thermo Fisher Getting a Good Deal With Life Technologies? at Motley Fool
10:39AM  What Does This $14 Billion Merger Deal Mean For The Future Of DNA Sequencing? at Forbes
10:39AM  What Does This $14 Billion Deal Mean For The Future Of DNA Sequencing? at Forbes
07:36AM  Thermo Fisher Agrees to Buy Life Technologies for $13.6 Billion at Bloomberg
14-Apr-13 07:16PM  Exclusive: Thermo Fisher nears $13 billion Life Tech deal Reuters
10-Apr-13 06:44PM  And the Bidding War Winner Is ... at Motley Fool
04:19PM  Illumina Stock Hits New 52-Week High (ILMN) at TheStreet
09-Apr-13 09:52PM  EXCLUSIVE-Thermo bids for Life Tech; PE firms finalizing offer-sources at Reuters
01:45PM  Synergy Pharma is a Buy and 4 More Analyst Notes to Read Now at Wall St. Cheat Sheet
08-Apr-13 05:45PM  Illumina Introduces TruSight Tumor Zacks
06:30AM  Illumina to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013 Business Wire
06-Apr-13 03:46AM  [$$] Earning Their Keep at Barrons.com
03:46AM  [$$] Earning Their Keep at Barrons.com
05-Apr-13 12:48PM  The Market Potential Of Life Technologies' Ion Proton Devices at Seeking Alpha
10:50AM  ResMed: CMS Takes Rungs Out Of Ladder at Seeking Alpha
04-Apr-13 06:30AM  Illumina Launches TruSight Tumor Content Set Business Wire
28-Mar-13 01:18PM  Affymetrix Inks Deal with UK Biobank Zacks
01:00AM  ILLUMINA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agr EDGAR Online
27-Mar-13 12:00PM  Illumina Technology Enables Findings of the Collaborative Oncological Gene-Environment Study (COGS) Business Wire
22-Mar-13 04:08PM  Life Sale Said to Shift to Strategics as Buyout Firms Go at Bloomberg
12:16PM  Life Sale Said to Shift to Strategics as Buyout Firms Go at Bloomberg
21-Mar-13 05:45PM  Illumina gets favorable ruling in patent lawsuit AP
04:29PM  InPlay: Illumina announces favorable outcome of its patent litigation against Life Technologies (LIFE) Briefing.com
04:28PM  Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc. Business Wire
09:00AM  Patients Should Be Told of Unexpected Gene Test Results at Bloomberg
19-Mar-13 04:41PM  Exclusive: Roche joins Life Tech auction; KKR, H&F team up - sources Reuters
02:34PM  Exclusive: Roche joins Life Tech auction, KKR and H&F team up - sources at Reuters
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Its sequencing platforms include HiSeq 2000, an instrument for high-throughput sequencing using sequencing by synthesis (SBS) technology; HiSeq 1500 that accommodates lower throughput needs; and MiSeq Personal Sequencing System that offers sequencing applications in a compact and economical instrument for individual researchers. The company's sequencing/array combination platforms comprise HiScanSQ that combines SBS technology and HiScan microarray analysis instrumentation into one system. Its array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of its array-based genetic analysis products. The company also offers various sample preparation and sequencing kits, such as standard sequencing kits; Infinium assay kits; paired-end genomic deoxyribonucleic acid (DNA) sample prep kits; and TruSeq SBS sequencing kits, as well as library preparation kits. In addition, it provides InfiniumHD Whole-Genome BeadChips, which are multi-sample DNA analysis microarrays; HumanOmni5-Quad, HumanOmni2.5, and HumanOmni1S BeadChips; agriculturally relevant genome panels; and iSelect Custom Genotyping BeadChips. Further, it offers CytoChip, a test for the investigation of genetic abnormalities associated with developmental delay or with complex leukemia's; Eco Real-Time polymerase chain reaction system; and sequencing and genotyping services. The company serves genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agri-genomics, and consumer genomics companies. It sells its products directly and through distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bouchard MichelVP, FinanceMay 15Option Exercise35.749,002321,70038,187May 17 07:08 PM
Naclerio NicholasSr VP, Corporate & Venture DevMay 15Option Exercise43.372,00086,74026,559May 17 07:08 PM
Bouchard MichelVP, FinanceMay 15Sale70.7114,2411,007,03029,961May 17 07:08 PM
Naclerio NicholasSr VP, Corporate & Venture DevMay 15Sale70.722,000141,44024,559May 17 07:08 PM
WALT DAVID RDirectorMay 15Sale70.735,000353,664968,988May 17 06:44 PM
Ronaghi MostafaSr VP & CTOMay 13Option Exercise42.6224,0001,022,87550,051May 14 02:49 PM
Ronaghi MostafaSr VP & CTOMay 13Sale68.8324,0001,651,93130,051May 14 02:49 PM
ORPIN TRISTANSr VP & Chief Commercial OfficMay 10Option Exercise20.0425,000501,00065,961May 14 02:31 PM
Naclerio NicholasSr VP, Corporate & Venture DevMay 10Option Exercise43.3725,0001,084,25039,559May 14 02:31 PM
Naclerio NicholasSr VP, Corporate & Venture DevMay 10Sale73.0025,0001,825,00024,559May 14 02:31 PM
ORPIN TRISTANSr VP & Chief Commercial OfficMay 10Sale69.6025,0001,740,00045,961May 14 02:31 PM
FLATLEY JAY TPresident & CEOMay 09Option Exercise10.4920,000209,700419,509May 13 07:47 PM
FLATLEY JAY TPresident & CEOMay 09Sale66.6320,0001,332,504399,509May 13 07:47 PM
ORPIN TRISTANSr VP & Chief Commercial OfficMay 07Option Exercise20.045,000100,20050,961May 09 07:53 PM
ORPIN TRISTANSr VP & Chief Commercial OfficMay 07Sale65.685,000328,40045,961May 09 07:53 PM
WALT DAVID RDirectorMay 01Sale64.155,000320,748973,988May 03 04:31 PM
Stapley MarcSr VP & CFOApr 30Option Exercise36.3015,000544,50039,851May 02 08:19 PM
Naclerio NicholasSr VP, Corporate & Venture DevApr 30Option Exercise43.3710,000433,70034,559May 02 08:19 PM
ORPIN TRISTANSVP & Chief Commercial OfficerApr 30Option Exercise20.045,000100,20050,961May 02 08:19 PM
ORPIN TRISTANSVP & Chief Commercial OfficerApr 30Sale65.005,000325,00045,961May 02 08:19 PM
Naclerio NicholasSr VP, Corporate & Venture DevApr 30Sale65.0010,000650,00024,559May 02 08:19 PM
Stapley MarcSr VP & CFOApr 30Sale65.0015,000975,00024,851May 02 08:19 PM
FLATLEY JAY TPresident & CEOApr 25Option Exercise10.4910,000104,850409,509Apr 29 09:15 PM
FLATLEY JAY TPresident & CEOApr 25Sale62.6110,000626,145399,509Apr 29 09:15 PM
Stapley MarcSr VP & CFOApr 23Option Exercise36.3010,710388,77337,561Apr 24 06:42 PM
Cabou ChristianSr VP & General CounselApr 23Option Exercise37.0413,937516,22659,490Apr 24 06:42 PM
Naclerio NicholasSr VP, Corporate & Venture DevApr 23Option Exercise43.372,00086,74026,559Apr 24 06:42 PM
Ronaghi MostafaSr Vice President & CTOApr 23Option Exercise41.0759,0002,423,12570,051Apr 24 08:04 PM
Ronaghi MostafaSr Vice President & CTOApr 23Sale60.0059,0003,540,00030,051Apr 24 08:04 PM
Naclerio NicholasSr VP, Corporate & Venture DevApr 23Sale60.002,000120,00024,559Apr 24 06:42 PM
Cabou ChristianSr VP & General CounselApr 23Sale60.0013,937836,22045,553Apr 24 06:42 PM
Stapley MarcSr VP & CFOApr 23Sale60.0012,710762,60024,851Apr 24 06:42 PM
Stapley MarcSr VP & CFOApr 22Option Exercise36.302,13377,42828,984Apr 24 06:42 PM
Stapley MarcSr VP & CFOApr 22Sale55.402,133118,16526,851Apr 24 06:42 PM
WALT DAVID RDirectorApr 17Option Exercise1.045,0005,175983,988Apr 19 08:50 PM
WALT DAVID RDirectorApr 17Sale57.555,000287,743978,988Apr 19 08:50 PM
Posard Matthew L.Sr VP & General ManagerApr 11Option Exercise30.4548,2321,468,58342,408Apr 15 08:06 PM
Stapley MarcSr VP & CFOApr 11Option Exercise36.3071025,77327,561Apr 15 08:07 PM
FLATLEY JAY TPresident & CEOApr 11Option Exercise10.4910,000104,850409,509Apr 15 08:06 PM
Stapley MarcSr VP & CFOApr 11Sale58.0071041,18026,851Apr 15 08:07 PM
FLATLEY JAY TPresident & CEOApr 11Sale57.2910,000572,862399,509Apr 15 08:06 PM
Posard Matthew L.Sr VP & General ManagerApr 11Sale57.9548,2322,795,04430,858Apr 15 08:06 PM
RASTETTER WILLIAM HDirectorApr 08Option Exercise1.0420,00020,70030,287Apr 10 07:39 PM
Cabou ChristianSr VP & General CounselApr 08Option Exercise37.0416,500611,16062,053Apr 10 07:38 PM
Stapley MarcSr VP & CFOApr 08Option Exercise36.307,500272,25036,026Apr 10 07:39 PM
Cabou ChristianSr VP & General CounselApr 08Sale55.0016,500907,50045,553Apr 10 07:38 PM
Stapley MarcSr VP & CFOApr 08Sale55.009,175504,62526,851Apr 10 07:39 PM
RASTETTER WILLIAM HDirectorApr 08Sale54.9520,0001,099,00010,287Apr 10 07:39 PM
WALT DAVID RDirectorApr 03Option Exercise1.045,0005,175983,988Apr 05 08:09 PM
WALT DAVID RDirectorApr 03Sale54.085,000270,420978,988Apr 05 08:09 PM
FLATLEY JAY TPresident & CEOMar 28Option Exercise10.495,00052,425404,509Apr 01 09:19 PM
FLATLEY JAY TPresident & CEOMar 28Sale54.115,000270,538399,509Apr 01 09:19 PM
Stapley MarcSr VP & CFOMar 20Option Exercise36.302,13377,42829,948Mar 22 06:36 PM
WALT DAVID RDirectorMar 20Option Exercise1.045,0005,175983,788Mar 22 09:18 PM
WALT DAVID RDirectorMar 20Sale52.605,000263,013978,988Mar 22 09:18 PM
Stapley MarcSr VP & CFOMar 20Sale52.692,133112,37828,526Mar 22 06:36 PM
FLATLEY JAY TPresident & CEOMar 14Option Exercise10.495,00052,425404,509Mar 15 11:14 AM
FLATLEY JAY TPresident & CEOMar 14Sale52.615,000263,075399,509Mar 15 11:14 AM
Stapley MarcSr VP & CFOMar 11Option Exercise36.304,468162,18832,994Mar 13 07:10 PM
Stapley MarcSr VP & CFOMar 11Sale53.714,468239,96028,526Mar 13 07:10 PM
WALT DAVID RDirectorMar 06Option Exercise1.045,0005,175983,988Mar 08 09:02 PM
WALT DAVID RDirectorMar 06Sale53.265,000266,322978,988Mar 08 09:02 PM
FLATLEY JAY TPresident & CEOFeb 28Option Exercise10.495,00052,425408,070Mar 04 08:21 PM
FLATLEY JAY TPresident & CEOFeb 28Sale49.555,000247,741403,070Mar 04 08:21 PM
FLATLEY JAY TPresident & CEOFeb 14Option Exercise10.495,00052,425408,070Feb 19 09:17 PM
FLATLEY JAY TPresident & CEOFeb 14Sale49.455,000247,253403,070Feb 19 09:17 PM
Cabou ChristianSr VP & General CounselJan 31Option Exercise13.7035,000479,50080,856Jan 31 09:26 PM
Cabou ChristianSr VP & General CounselJan 31Sale50.5435,0001,768,93945,856Jan 31 09:26 PM
Cabou ChristianSr VP & General CounselJan 30Option Exercise26.9455,5001,495,19375,856Jan 31 09:26 PM
Cabou ChristianSr VP & General CounselJan 30Sale50.7555,5002,816,52645,856Jan 31 09:26 PM
FLATLEY JAY TPresident & CEOJan 24Option Exercise10.495,00052,425399,357Jan 25 07:58 PM
FLATLEY JAY TPresident & CEOJan 24Sale50.915,000254,575394,357Jan 25 07:58 PM
FLATLEY JAY TPresident & CEOJan 10Option Exercise10.495,00052,425399,357Jan 14 08:15 PM
FLATLEY JAY TPresident & CEOJan 10Sale52.935,000264,652394,357Jan 14 08:15 PM
FLATLEY JAY TPresident and CEODec 27Option Exercise10.4910,000104,850404,357Dec 31 05:16 PM
Lewis Mark LSr VP & General ManagerDec 20Option Exercise37.0424,500907,48066,385Dec 21 04:11 PM
Lewis Mark LSr VP & General ManagerDec 20Sale56.2124,5001,377,14541,885Dec 21 04:11 PM
Lewis Mark LSr VP & General ManagerDec 19Option Exercise21.375,000106,85046,885Dec 20 05:45 PM
Lewis Mark LSr VP & General ManagerDec 19Sale51.875,000259,36041,885Dec 20 05:45 PM
FLATLEY JAY TPresident & CEODec 13Option Exercise10.495,00052,425399,357Dec 17 08:02 PM
FLATLEY JAY TPresident & CEODec 13Sale52.745,000263,719394,357Dec 17 08:02 PM
FLATLEY JAY TPresident & CEONov 23Option Exercise10.495,00052,425399,357Nov 27 12:17 PM
FLATLEY JAY TPresident & CEONov 23Sale53.325,000266,575394,357Nov 27 12:17 PM
Lewis Mark LSr VP & GM Molecular BiologyNov 19Option Exercise21.375,000106,85046,885Nov 21 05:18 PM
Lewis Mark LSr VP & GM Molecular BiologyNov 19Sale50.005,000250,00041,885Nov 21 05:18 PM
FLATLEY JAY TPresident & CEONov 08Option Exercise4.305,00021,500399,357Nov 13 06:49 PM
FLATLEY JAY TPresident & CEONov 08Sale47.995,000239,937394,357Nov 13 06:49 PM
FLATLEY JAY TPresident & CEOOct 25Option Exercise4.305,00021,500399,357Oct 29 07:01 PM
FLATLEY JAY TPresident & CEOOct 25Sale46.785,000233,902394,357Oct 29 07:01 PM
FLATLEY JAY TPresident & CEOOct 11Option Exercise4.305,00021,500399,357Oct 15 07:43 PM
FLATLEY JAY TPresident & CEOOct 11Sale51.585,000257,875394,357Oct 15 07:43 PM
HENRY CHRISTIAN OSr VP, General Manager GenomicOct 09Option Exercise26.2610,000262,62542,745Oct 11 05:09 PM
HENRY CHRISTIAN OSr VP, General Manager GenomicOct 09Sale51.7010,000516,96237,745Oct 11 05:09 PM
FLATLEY JAY TPresident & CEOSep 27Option Exercise4.305,00021,500399,357Oct 01 06:12 PM
FLATLEY JAY TPresident & CEOSep 27Sale46.875,000234,340394,357Oct 01 06:12 PM
HENRY CHRISTIAN OSr VP, General Manager GenomicSep 14Option Exercise20.0430,000601,20067,745Sep 18 07:43 PM
HENRY CHRISTIAN OSr VP, General Manager GenomicSep 14Sale48.0030,0001,440,00037,745Sep 18 07:43 PM
FLATLEY JAY TPresident & CEOSep 13Option Exercise4.305,00021,500399,357Sep 17 08:03 PM
FLATLEY JAY TPresident & CEOSep 13Sale45.005,000225,000394,357Sep 17 08:03 PM
EASTHAM KARINDirectorJun 01Option Exercise9.0610,00090,55012,360Jun 05 07:55 PM
open in yahoo | open in reuters | open in google